From Nasdaq: 2025-05-05 09:13:00

The Medical sector’s first-quarter earnings season is underway, with pharma/biotech and medical device companies reporting results. Companies like J&J Merck, Bristol Myers, Novartis, and Amgen exceeded expectations, while Pfizer, Eli Lilly, Sanofi, and Biogen had mixed results. Regeneron missed estimates. Earnings rose 60.5% year over year, with revenues up 7.8%.

45% of Medical sector companies reported earnings, with 66.7% beating both earnings and revenue estimates. Earnings increased by 60.5% year over year, while revenues rose by 7.8%. First-quarter earnings for the sector are projected to rise by 40% and revenues by 8.3%.

Five drug/biotech companies – Novo Nordisk, Pacira BioSciences, Ultragenyx Pharmaceuticals, Acadia Pharmaceuticals, and Denali Therapeutics – are expected to perform well in their upcoming quarterly results. Companies with positive Earnings ESP and Zacks Rank #1, 2, or 3 have a 70% chance of an earnings beat.

Novo Nordisk is expected to report earnings of 92 cents per share and $11.33 billion in revenues. Sales of diabetes and obesity care products are likely to have boosted revenues in the first quarter. Novo Nordisk’s performance has varied in recent quarters, with an average surprise of 1.97%.

Pacira BioSciences, with an Earnings ESP of +34.51%, is projected to report earnings of 57 cents per share and revenues of $174.96 million. Growing sales of Exparel and other products are expected to contribute to revenue growth in the first quarter.

Ultragenyx Pharmaceuticals is expected to report a loss of $1.54 per share and revenues of $141.99 million. Revenue growth is likely to be driven by increasing sales of Crysvita and other products, contributing to top-line growth in the first quarter.



Read more at Nasdaq:: 5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates